In ALK-rearranged NSCLC, we showed that sequencing single CTCs unravelled both “on-target and off-target” acquired genomic alterations to ALK-TKIs, providing new insight into the therapeutic resistance landscape in this patient subset [26, 27]. Here, ALK is linked to non-small cell lung carcinoma.